Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers

NCT ID: NCT02442739

Last Updated: 2018-11-06

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: EARLY_PHASE1
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-08-15
• Study Completion Date: 2017-11-03

Brief Summary

The primary purpose of this study is to see if it is safe to give patients with pancreatic or head and neck cancer a low dose of the FDA approved anesthetic drug ketamine at the same time they receive radiation and/or chemotherapy for their cancer treatment to prevent depression and its effects. Researchers would also like to see if giving ketamine at the same time as cancer treatment is practical and reasonably acceptable to the patient.

New onset depression is highly frequent in those with head and neck cancer, and depression has many negative consequences for outcomes in those patients. Depression has been known to have greater incidence in pancreatic cancer patients than in patients with other malignancies.

Therefore, investigators would also like to see if giving patients ketamine during their routine cancer treatment will prevent the onset of depression and its negative effects on cancer treatment outcomes, and also help with anxiety, pain, and quality of life. The study will also use a placebo to compare to the good and/or bad effects of ketamine. A placebo is not an active drug and it will be look the same as ketamine, as a liquid to be taken by mouth.

Ketamine is approved by the U.S. Food and Drug Administration (FDA) as a general anesthetic by itself for some diagnostic and surgical procedures or combined with other general anesthetic agents. It has also been shown to reduce cancer pain. Ketamine is considered experimental in this study because it is not approved by the FDA for the prevention of depression.

Detailed Description

This is a prospective, single center, double blind, randomized, two-arm feasibility study of oral ketamine versus placebo for the prevention of depression in non-depressed patients with head and neck or pancreatic cancer undergoing curative intent cancer therapy. Approximately 40 patients with head and neck cancer or pancreatic cancer about to undergo cancer therapy will be randomized 1:1 to receive study treatment with one of the following regimens:

• Arm A: weekly oral administration of 0.5 mg/kg ketamine
• Arm B: weekly oral administration of placebo

Consenting patients will undergo screening procedures, and if eligible, a baseline interview and brief questionnaires regarding depression, mental and emotional health, and quality of life assessments.

Study treatment will be administered for 12 weeks unless the patient experiences unacceptable toxicities, exhibits moderate to severe depressive symptoms, or withdraws consent. Patients on the placebo treatment arm will not be eligible to cross over to the ketamine arm at evidence of depression but will be removed from the study and treated with standard medical management for depression.

Patients will be asked to complete psychosocial measurements every two weeks, before study medication/placebo administration, while on study treatment and monthly during a five-month follow-up period.

Conditions

Head and Neck Cancer; Pancreatic Cancer; Depression

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Ketamine

oral ketamine 0.5 mg/kg mixed with syrup

Group Type: EXPERIMENTAL

Ketamine

Intervention Type: DRUG

Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.

Placebo

oral placebo (syrup)

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo syrup will be given by mouth once a week for 12 weeks.

Interventions

Ketamine

Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.

Intervention Type: DRUG

Placebo

Placebo syrup will be given by mouth once a week for 12 weeks.

Intervention Type: OTHER

Other Intervention Names

Ketalar

Eligibility Criteria

Inclusion Criteria

1. Ability to understand and the willingness to sign a written informed consent.

2. Stage -II-IV epidermoid cancer of the head and neck OR stage III-IV pancreatic cancer, with prognosis of at least three months, per oncologist.

3. Within two weeks of starting or from having started, curative intent therapy for head and neck cancer.

4. Age ≥ 18 years.

5. Adequate liver function as defined by:

• ALT < 5 X institutional upper limit of normal (ULN)
• AST < 5 X institutional ULN
• Total bilirubin < 5 X institutional ULN

6. Both men and women of all races and ethnic groups are eligible for this trial.

Exclusion Criteria

8. Women of child-bearing potential and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform the study team and her treating physician immediately. Urine pregnancy testing will be done throughout the trial for women of childbearing potential.

9. Must read and understand English fluently.

1. Receiving another investigational agent on a clinical trial that prohibits participation in other studies of investigational agents.

2. Meets Mini International Neuropsychiatric interview (MINI) criteria for major depression, schizophrenia, bipolar illness, delirium or psychosis.

3. Has moderate to severe depression according to both the Quick Inventory of Depressive Symptomatology-Self Rated 16 (QIDS-SR-16) score of ≥ 11 AND a Hospital Anxiety and Depression Scale (HADS) Depression subscale score of ≥ 8.

4. Has Suicidal Risk Assessment (SRA) scores ≥ 6.

5. Use of monoamine oxidase inhibitors within 14 days of study entry.

6. Diagnosed with melanoma or lymphoma cancer of the head and neck.

7. Diagnosed with Stage I or II pancreatic cancer or with anticipated survival of less than three months.

8. History of allergic reactions or hypersensitivity to ketamine.

9. Severe cardiac insufficiency (NYHA III or IV), with uncontrolled and/or unstable cardiac or coronary artery disease.

10. History of significant tachyarrhythmia, severe angina, or myocardial ischemia

11. Poorly controlled hypertension (Systolic Blood Pressure > 180 mmHG or Diastolic Blood Pressure > 100 mmHG), with or without antihypertensives.

12. If a woman is or becomes pregnant or is nursing at any time before or during the treatment period, she will be excluded from the study.

13. Score of ≥ 8 on the WHO Alcohol Use Disorders Identification Test (AUDIT, sensitivity of 0.8).

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Cedars-Sinai Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Scott A. Irwin, MD, PhD

Associate Professor, Psychiatry & Behavioral Neurosciences

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Scott Irwin, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Cedars-Sinal Medical Center

Locations

Cedars-Sinai Medical Center

Los Angeles, California, United States

Countries

United States

Other Identifiers

1R21CA197023-01A1

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IIT2015-22-IRWIN-KETPREVE

Identifier Type: -

Identifier Source: org_study_id